Safety and efficacy of closed-loop arbutamine stress echocardiography for detection of coronary artery disease. International Arbutamine Study Group

Use of pharmaceuticals in noninvasive cardiovascular diagnosis

A number of pharmaceuticals are employed as diagnostic agents for cardiovascular diseases. Four groups of agents are reviewed here: 1) vasoactive substances employed as adjuncts to physical maneuvers in diagnosis of structural heart disease; 2) vasodilators used to produce heterogeneity of coronary flow; 3) sympathomimetic agents simulating the effects of exercise on the heart for the purpose of detection of coronary artery stenosis; and 4) ultrasonic contrast agents used to enhance myocardial imaging for the assessment of segmental wall motion. In the first group are amyl nitrate, a vasodilator, and methoxamine and phenylephrine, both vasopressors. The vasodilators of the second group are dipyridamole and adenosine. When combined with scintigraphic perfusion imaging or with echocardiographic assessment of segmental wall motion, these agents can detect single- or multiple-vessel coronary artery disease with sensitivity and specificity comparable to submaximal exercise. They are especially useful for preoperative risk assessment before noncardiac surgery. The sympathomimetic agents of the third group, dobutamine and arbutamine, increase myocardial contractility and heart rate, and dilate the peripheral vasculature. As with the vasodilators, when combined with nuclear or echocardiographic techniques they are equivalent to exercise in detection of coronary disease. They are especially useful in patients with bronchospastic disease and for assessment of myocardial viability. Agents from groups 2 and 3 have acceptable side-effect and safety profiles. The last group reviewed includes echocardiographic contrast agents that, in this investigative setting, are employed to enhance detection of segmental wall motion when used with agents from groups 2 and 3.

Pharmacological stress agents for evaluation of ischemic heart disease

Ischemic heart disease is the leading cause of death in the developed countries for those older than 65 years of age. In patients suspected to have coronary artery disease a stress test should be performed to identify the vulnerability of the myocardium to ischemia. As a rule of thumb, the evaluation of coronary artery disease is best done by exercise stress test. In patients who are not able to exercise adequately, pharmacological stress agents are used. The commonly used agents are the coronary vasodilators, adenosine and dipyridamole and the catecholamines, dobutamine and arbutamine. These agents are combined with imaging techniques to increase the sensitivity and specificity of the test. These agents have been widely used and have an excellent safety profile. Another advantage in using pharmacological stress agents is that they do not affect the image quality, especially with echocardiography and magnetic resonance imaging. Ongoing developments hold promise for safer and more reliable pharmacological stress agents in the future.

Overview of stress echocardiography: uses, advantages, and limitations

Responses of the heart to changes in our environment are probably even more important than how the heart functions at rest. Accordingly, stress testing with noninvasive imaging has become important for diagnosis, prognosis, and monitoring the effects of therapy. Echocardiography at rest and with stress permits characterization of global and segmental left ventricular function as well as valvular structure and function. Moreover, echocardiography can be performed during or after a number of different physical or even mental stressors. Advantages of stress echocardiography include its ready availability, relatively low capital cost, and incremental value in that it allows characterization of cardiac anatomy as well as the myocardial response to a potentially ischemic stimulus. Moreover, echocardiography has the potential to image myocardial perfusion along with wall motion and wall thickening. Substantial literature has now been accumulated on the value of stress echocardiography for the diagnosis of ischemic disease, preoperative risk assessment, and assessment of myocardial viability. Echocardiography has compared generally well with nuclear imaging techniques for the detection of angiographic coronary artery disease. Overall sensitivity, however, has been slightly less, particularly for the detection of single-vessel coronary disease, although specificity has been on average somewhat higher than nuclear cardiology techniques. Because of the potential for variability in study acquisition as well as interpretation, careful safeguards need to be employed. Specifically, meticulous technique needs to be applied to obtain high-quality images and to assure that those images are obtained promptly after treadmill exercise stress. Only readers with specific interest and expertise should interpret stress echocardiography studies. Continuing efforts need to be made to assess and minimize variability and to assure continuing quality improvement. Advances in instrumentation, including evolving technology for real-time 3-dimensional imaging, and echocardiography contrast assessment of myocardial perfusion will likely improve the sensitivity of echocardiography and further extend its usefulness.

Pharmacologic stress echocardiography. Dobutamine and arbutamine stress testing

Pharmacologic stress testing is an important noninvasive method for evaluating patients with known or suspected coronary artery disease who are unable to adequately exercise. Pharmacologic stress echocardiography using dobutamine has been developed over the last 10 to 15 years as an alternative to vasodilator stress testing using nuclear perfusion imaging. As experience has grown, digital subtraction echocardiogram has been shown to be a safe, convenient, and reliable method for stress testing in a variety of patient populations. Digital subtraction echocardiogram has comparable sensitivity, specificity, and accuracy when compared to other stress testing methods which employ cardiac imaging and is superior to the exercise echocardiogram. It has certain advantages over nuclear perfusion imaging in terms of cost and convenience. The recent addition of arbutamine echocardiography (which has been shown to be comparable to digital subtraction echocardiogram) provides another alternative method for pharmacologic stress testing. Continued improvement in echocardiographic image quality and the development of new technologies such as tissue harmonic imaging and contrast echocardiography will hopefully improve the echocardiographic evaluation of wall motion therefore increasing the diagnostic accuracy of echocardiographic stress testing.